Capital Management Associates Inc Takes Position in AbbVie Inc. (NYSE:ABBV)

Capital Management Associates Inc acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,540 shares of the company's stock, valued at approximately $323,000.

A number of other institutional investors have also recently bought and sold shares of ABBV. EnRich Financial Partners LLC boosted its position in AbbVie by 196.4% during the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock valued at $29,000 after purchasing an additional 110 shares during the last quarter. Abound Financial LLC acquired a new stake in AbbVie during the first quarter valued at $30,000. Prudent Man Investment Management Inc. acquired a new stake in shares of AbbVie in the fourth quarter worth about $32,000. Siemens Fonds Invest GmbH lifted its position in shares of AbbVie by 197.6% in the fourth quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company's stock worth $32,000 after buying an additional 119,141 shares during the last quarter. Finally, Pinney & Scofield Inc. acquired a new stake in shares of AbbVie in the fourth quarter worth about $36,000. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Stock Performance

ABBV traded down $1.84 on Monday, hitting $187.44. 10,162,022 shares of the stock traded hands, compared to its average volume of 6,269,186. AbbVie Inc. has a 52 week low of $163.81 and a 52 week high of $218.66. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $331.09 billion, a PE ratio of 79.76, a P/E/G ratio of 1.26 and a beta of 0.48. The business has a fifty day moving average price of $187.37 and a two-hundred day moving average price of $188.68.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The firm had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. During the same period in the previous year, the company posted $2.31 earnings per share. The company's quarterly revenue was up 8.4% compared to the same quarter last year. On average, research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 annualized dividend and a yield of 3.50%. AbbVie's dividend payout ratio is 279.15%.

Analyst Ratings Changes

A number of analysts have weighed in on ABBV shares. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Evercore ISI boosted their price target on AbbVie from $204.00 to $205.00 and gave the stock an "outperform" rating in a research report on Monday, April 28th. Bank of America boosted their price target on AbbVie to $204.00 and gave the stock a "hold" rating in a research report on Monday, June 9th. Guggenheim boosted their price target on AbbVie from $214.00 to $216.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Finally, Citigroup boosted their price target on AbbVie to $205.00 and gave the stock a "hold" rating in a research report on Wednesday, June 11th. Eight equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $211.29.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.